Literature DB >> 30456592

Atrial fibrillation in hypertrophic cardiomyopathy: prevalence, clinical impact, and management.

Lohit Garg1, Manasvi Gupta2, Syed Rafay Ali Sabzwari3, Sahil Agrawal4, Manyoo Agarwal5, Talha Nazir3, Jeffrey Gordon3, Babak Bozorgnia3, Matthew W Martinez3.   

Abstract

Hypertrophic cardiomyopathy (HCM) is the most common hereditary cardiomyopathy characterized by left ventricular hypertrophy and spectrum of clinical manifestation. Atrial fibrillation (AF) is a common sustained arrhythmia in HCM patients and is primarily related to left atrial dilatation and remodeling. There are several clinical, electrocardiographic (ECG), and echocardiographic (ECHO) features that have been associated with development of AF in HCM patients; strongest predictors are left atrial size, age, and heart failure class. AF can lead to progressive functional decline, worsening heart failure and increased risk for systemic thromboembolism. The management of AF in HCM patient focuses on symptom alleviation (managed with rate and/or rhythm control methods) and prevention of complications such as thromboembolism (prevented with anticoagulation). Finally, recent evidence suggests that early rhythm control strategy may result in more favorable short- and long-term outcomes.

Entities:  

Keywords:  Antiarrhythmic agents; Atrial fibrillation; Hypertrophic cardiomyopathy; Treatment

Mesh:

Substances:

Year:  2019        PMID: 30456592     DOI: 10.1007/s10741-018-9752-6

Source DB:  PubMed          Journal:  Heart Fail Rev        ISSN: 1382-4147            Impact factor:   4.214


  63 in total

1.  Effectiveness of atrial fibrillation surgery in patients with hypertrophic cardiomyopathy.

Authors:  Michael S Chen; Patrick M McCarthy; Harry M Lever; Nicholas G Smedira; Bruce L Lytle
Journal:  Am J Cardiol       Date:  2004-02-01       Impact factor: 2.778

2.  2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the American Association for Thoracic Surgery, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons.

Authors:  Bernard J Gersh; Barry J Maron; Robert O Bonow; Joseph A Dearani; Michael A Fifer; Mark S Link; Srihari S Naidu; Rick A Nishimura; Steve R Ommen; Harry Rakowski; Christine E Seidman; Jeffrey A Towbin; James E Udelson; Clyde W Yancy
Journal:  J Am Coll Cardiol       Date:  2011-11-08       Impact factor: 24.094

3.  In patients with hypertrophic cardiomyopathy myocardial fibrosis is associated with both left ventricular and left atrial dysfunction.

Authors:  Christian Prinz; Frank Van Buuren; Nicola Bogunovic; Thomas Bitter; Lothar Faber; Dieter Horstkotte
Journal:  Acta Cardiol       Date:  2012-04       Impact factor: 1.718

Review 4.  Genetics of inherited cardiomyopathy.

Authors:  Daniel Jacoby; William J McKenna
Journal:  Eur Heart J       Date:  2011-08-02       Impact factor: 29.983

5.  Clinical Profile and Consequences of Atrial Fibrillation in Hypertrophic Cardiomyopathy.

Authors:  Ethan J Rowin; Anais Hausvater; Mark S Link; Patrick Abt; William Gionfriddo; Wendy Wang; Hassan Rastegar; N A Mark Estes; Martin S Maron; Barry J Maron
Journal:  Circulation       Date:  2017-09-15       Impact factor: 29.690

6.  Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter: the symptomatic atrial fibrillation investigative research on dofetilide (SAFIRE-D) study.

Authors:  S Singh; R G Zoble; L Yellen; M A Brodsky; G K Feld; M Berk; C B Billing
Journal:  Circulation       Date:  2000-11-07       Impact factor: 29.690

7.  Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group.

Authors:  C Torp-Pedersen; M Møller; P E Bloch-Thomsen; L Køber; E Sandøe; K Egstrup; E Agner; J Carlsen; J Videbaek; B Marchant; A J Camm
Journal:  N Engl J Med       Date:  1999-09-16       Impact factor: 91.245

8.  Continuous vs episodic prophylactic treatment with amiodarone for the prevention of atrial fibrillation: a randomized trial.

Authors:  Sheba Ahmed; Michiel Rienstra; Harry J G M Crijns; Thera P Links; Ans C P Wiesfeld; Hans L Hillege; Hans A Bosker; Dirk J A Lok; Dirk J Van Veldhuisen; Isabelle C Van Gelder
Journal:  JAMA       Date:  2008-10-15       Impact factor: 56.272

9.  Stroke and Embolic Events in Hypertrophic Cardiomyopathy: Risk Stratification in Patients Without Atrial Fibrillation.

Authors:  Shintaro Haruki; Yuichiro Minami; Nobuhisa Hagiwara
Journal:  Stroke       Date:  2016-03-03       Impact factor: 7.914

Review 10.  Rate- and rhythm-control therapies in patients with atrial fibrillation: a systematic review.

Authors:  Sana M Al-Khatib; Nancy M Allen LaPointe; Ranee Chatterjee; Matthew J Crowley; Matthew E Dupre; David F Kong; Renato D Lopes; Thomas J Povsic; Shveta S Raju; Bimal Shah; Andrzej S Kosinski; Amanda J McBroom; Gillian D Sanders
Journal:  Ann Intern Med       Date:  2014-06-03       Impact factor: 25.391

View more
  12 in total

1.  The predictive value of left ventricular and left atrial mechanics for atrial fibrillation and heart failure in hypertrophic cardiomyopathy: a prospective cohort study.

Authors:  Thomas Zegkos; Dimitris Ntelios; Despoina Parcharidou; Sotiris Katranas; Theofilos Panagiotidis; Christos A Papanastasiou; Efstratios Karagiannidis; Pavlos Rouskas; Vassilis Vassilikos; Haralampos Karvounis; Georgios K Efthimiadis
Journal:  Int J Cardiovasc Imaging       Date:  2021-04-05       Impact factor: 2.357

2.  Clinical Outcomes of Warfarin Initiation in Advanced Chronic Kidney Disease Patients With Incident Atrial Fibrillation.

Authors:  Manyoo A Agarwal; Praveen K Potukuchi; Keiichi Sumida; Adnan Naseer; Miklos Z Molnar; Lekha K George; Santhosh K Koshy; Elani Streja; Fridtjof Thomas; Kamyar Kalantar-Zadeh; Csaba P Kovesdy
Journal:  JACC Clin Electrophysiol       Date:  2020-09-16

3.  Clinical Utility of Left Atrial Asynchrony and Mechanical Function in Patients with Hypertrophic Cardiomyopathy.

Authors:  Ozkan Candan; Cetin Gecmen; Muzaffer Kahyaoğlu; Zeki Şimsek; Mehmet Çelik; Abdulkadir Uslu; Cevat Kirma
Journal:  Acta Cardiol Sin       Date:  2022-03       Impact factor: 2.672

4.  Collagen Cross-Linking Is Associated With Cardiac Remodeling in Hypertrophic Obstructive Cardiomyopathy.

Authors:  Xuanye Bi; Yanyan Song; Yunhu Song; Jiansong Yuan; Jingang Cui; Shihua Zhao; Shubin Qiao
Journal:  J Am Heart Assoc       Date:  2020-12-25       Impact factor: 5.501

5.  PRRX1 Loss-of-Function Mutations Underlying Familial Atrial Fibrillation.

Authors:  Xiao-Juan Guo; Xing-Biao Qiu; Jun Wang; Yu-Han Guo; Chen-Xi Yang; Li Li; Ri-Feng Gao; Zun-Ping Ke; Ruo-Min Di; Yu-Min Sun; Ying-Jia Xu; Yi-Qing Yang
Journal:  J Am Heart Assoc       Date:  2021-11-30       Impact factor: 6.106

Review 6.  Thromboembolism in Patients with Hypertrophic Cardiomyopathy.

Authors:  Lu Liu; Zheng Liu; Xiaoping Chen; Sen He
Journal:  Int J Med Sci       Date:  2021-01-01       Impact factor: 3.738

7.  The preoperative glomerular filtration rate predicts new-onset postoperative atrial fibrillation in patients with hypertrophic obstructive cardiomyopathy who undergo isolated septal myectomy.

Authors:  Yanhai Meng; Shuiyun Wang; Ping Liu; Yanbo Zhang; Bing Tang; Changsheng Zhu; Shengwei Wang; Qiulan Yang; Tao Lu; Changrong Nie
Journal:  J Thorac Dis       Date:  2021-03       Impact factor: 2.895

8.  Risk Factors of Pulmonary Arterial Hypertension and Its Relationship With Atrial Fibrillation in Patients With Obstructive Hypertrophic Cardiomyopathy.

Authors:  Changrong Nie; Changsheng Zhu; Minghu Xiao; Zhengyang Lu; Qiulan Yang; Yanhai Meng; Rong Wu; Shuiyun Wang
Journal:  Front Cardiovasc Med       Date:  2021-07-07

9.  Characteristics of left atrial remodeling in patients with atrial fibrillation and hypertrophic cardiomyopathy in comparison to patients without hypertrophy.

Authors:  Sotirios Nedios; Borislav Dinov; Timm Seewöster; Frank Lindemann; Sergio Richter; Arash Arya; Nikolaos Dagres; Daniela Husser; Andreas Bollmann; Gerhard Hindricks; Andreas Müssigbrodt
Journal:  Sci Rep       Date:  2021-06-14       Impact factor: 4.379

10.  Implication of Apnea-Hypopnea Index, a Measure of Obstructive Sleep Apnea Severity, for Atrial Fibrillation in Patients With Hypertrophic Cardiomyopathy.

Authors:  Haobo Xu; Juan Wang; Jiansong Yuan; Fenghuan Hu; Weixian Yang; Chao Guo; Xiaoliang Luo; Rong Liu; Jingang Cui; Xiaojin Gao; Yushi Chun; Shubin Qiao
Journal:  J Am Heart Assoc       Date:  2020-04-16       Impact factor: 5.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.